Globus Medical, Inc. $GMED Stock Position Lowered by State of Wyoming

State of Wyoming decreased its position in Globus Medical, Inc. (NYSE:GMED) by 62.1% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 5,015 shares of the medical device company’s stock after selling 8,233 shares during the period. State of Wyoming’s holdings in Globus Medical were worth $432,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GMED. Sanctuary Advisors LLC boosted its position in shares of Globus Medical by 2.3% in the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after buying an additional 151 shares during the period. SBI Securities Co. Ltd. grew its holdings in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares in the last quarter. Parallel Advisors LLC raised its position in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the period. EverSource Wealth Advisors LLC raised its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Finally, Allworth Financial LP lifted its stake in Globus Medical by 1.6% in the 4th quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock worth $1,095,000 after acquiring an additional 199 shares in the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Price Performance

Shares of GMED stock opened at $76.46 on Friday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The stock’s 50-day moving average is $79.79 and its two-hundred day moving average is $86.06. The firm has a market cap of $10.38 billion, a P/E ratio of 17.78, a PEG ratio of 1.58 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current year.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 18.38% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GMED has been the subject of a number of research reports. Piper Sandler decreased their price objective on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Truist Financial reduced their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Wells Fargo & Company lowered their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada cut their target price on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical has an average rating of “Moderate Buy” and an average price target of $103.75.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.